Powell investigation, Google's AI shopping push and more: Morning Squawk

In a significant development, Federal Reserve Chair Jerome Powell is now facing a criminal investigation related to the renovations of the central bank's headquarters. This announcement has intensified the ongoing tension between Powell and President Donald Trump concerning the Federal Reserve's approach to interest rates. As the trading week begins, investors are particularly focused on upcoming bank earnings reports. This week marks the beginning of a new earnings season, with JPMorgan Chase CEO Jamie Dimon celebrating his 20th anniversary in the role. Speculation is growing about Dimon’s potential departure, especially as he approaches his 70th birthday, raising questions about the bank's future leadership and stability. In other news, Walmart has partnered with Google to enhance the shopping experience through artificial intelligence. Google's AI assistant, Gemini, will assist customers in finding and purchasing products from Walmart and Sam’s Club. While the launch date remains uncertain, the partnership aims to establish a stronger foothold in the retail sector, following Walmart’s previous alliance with OpenAI's ChatGPT. Meanwhile, Boeing is poised to announce its highest airplane delivery figures since 2018, signaling a potential turnaround for the aerospace giant after years of challenges. The company plans to increase production of its 737 Max and 787 Dreamliners in response to the recovering market. In the airline industry, Allegiant has announced it will acquire budget rival Sun Country in a deal valued at $1.5 billion. This merger comes as low-cost carriers continue to navigate rising operational costs in the post-pandemic landscape. On the health front, the GLP-1 market is evolving with the introduction of daily obesity pills from Novo Nordisk. These new medications are expected to provide a simpler alternative to the traditional weekly injections, potentially attracting a broader range of patients who prefer oral options over needles. Eli Lilly is also anticipated to secure regulatory approval for its similar product in the near future. As the week unfolds, investors are advised to stay informed on these key developments that could impact market dynamics.